Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.61 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.61 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | GGT1 | P19440 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1332285 | 0.93 | PTGS2 (0.69) | HSD17B10KDM4ELMNACYP1A2CYP2C9 | |
| SCHEMBL133699 | 0.93 | PTGS2 (0.69) | HSD17B10KDM4ELMNACYP1A2CYP2C9 | |
| SCHEMBL30269568 | 0.93 | PTGS2 (0.69) | HSD17B10KDM4ELMNACYP1A2CYP2C9 | |
| Acetone SCHEMBL28889942 | 0.91 | PTGS2 (0.67) | HSD17B10KDM4ELMNACYP1A2CYP2C9 | |
| Diplosalsalate SCHEMBL25398 | 0.84 | KDM4E (1.00) | HSD17B10KDM4ELMNACYP1A2CYP2C9 | |
| Diplosalsalate SCHEMBL30590970 | 0.84 | KDM4E (1.00) | HSD17B10KDM4ELMNACYP1A2CYP2C9 | |
| SCHEMBL2473332 | 0.84 | KDM4E (1.00) | HSD17B10KDM4ELMNACYP1A2CYP2C9 | |
| Diplosalsalate SCHEMBL25303461 | 0.83 | KDM4E (0.97) | HSD17B10KDM4ELMNACYP1A2CYP2C9 | |
| Guacetisal SCHEMBL29368893 | 0.83 | KDM4E (0.73) | HSD17B10KDM4ELMNACYP1A2CYP2C9 | |
| Guacetisal SCHEMBL948974 | 0.83 | KDM4E (0.73) | HSD17B10KDM4ELMNACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099491-A1 | PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES WITH HIGH PENETRATION PRODRUGS OF ASPIRIN AND OTHER NSAIDS | TECHFIELDS INC. (JP) | 2025-03-27 | — | — | US | disclosed |
| EP-4465993-A1 | PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES WITH HIGH PENETRATION PRODRUGS OF ASPIRIN AND OTHER NSAIDS | TECHFIELDS INC. (US) | 2024-11-27 | — | — | EP | disclosed |
| CN-118632699-A | Prevention or treatment of cardiovascular disease with high penetration prodrugs of aspirin and other non-steroidal anti-inflammatory drugs | 苏州泰飞尔医药有限公司 | 2024-09-10 | — | — | CN | disclosed |
| WO-2023134732-A9 | PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES WITH HIGH PENETRATION PRODRUGS OF ASPIRIN AND OTHER NSAIDS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-08-08 | — | — | WO | disclosed |
| WO-2023134732-A1 | PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES WITH HIGH PENETRATION PRODRUGS OF ASPIRIN AND OTHER NSAIDS | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-07-20 | — | — | WO | disclosed |
| US-20210353579-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO LTD (CN) | 2021-11-18 | — | — | US | disclosed |
| CN-113387809-A | Aspirin eugenol ester process impurity and preparation method thereof | 中国农业科学院兰州畜牧与兽药研究所 | 2021-09-14 | — | — | CN | disclosed |
| EP-3004049-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | CELLIX BIO PRIVATE LTD (IN) | 2018-09-05 | — | — | EP | disclosed |
| US-9872846-B2 | High penetration compositions and uses thereof | TECHFIELDS PHARMA CO., LTD. (CN) | 2018-01-23 | — | — | US | disclosed |
| US-20170209404-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | PREMIER RESEARCH INTERNATIONAL, LLC | 2017-07-27 | — | — | US | disclosed |
| US-20150183728-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | CELLIX BIO PRIVATE LIMITED (IN) | 2015-07-02 | — | — | US | disclosed |
| US-20150183728-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | CELLIX BIO PRIVATE LIMITED (IN) | 2015-07-02 | — | — | US | disclosed |
| US-8952068-B2 | Compositions for the treatment of diabetes and pre-diabetes | CELLIXBIO PRIVATE LIMITED (IN) | 2015-02-10 | — | — | US | disclosed |
| US-8952068-B2 | Compositions for the treatment of diabetes and pre-diabetes | CELLIXBIO PRIVATE LIMITED (IN) | 2015-02-10 | — | — | US | disclosed |
| US-8952068-B2 | Compositions for the treatment of diabetes and pre-diabetes | CELLIXBIO PRIVATE LIMITED (IN) | 2015-02-10 | — | — | US | disclosed |
| WO-2014195961-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | KANDULA MAHESH (IN) | 2014-12-11 | — | — | WO | disclosed |
| US-20140357680-A1 | COMPOSITIONS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | CELLIXBIO PRIVATE LIMITED (IN) | 2014-12-04 | — | — | US | disclosed |
| US-20140357680-A1 | COMPOSITIONS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | CELLIXBIO PRIVATE LIMITED (IN) | 2014-12-04 | — | — | US | disclosed |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO., LTD. (CN) | 2009-09-24 | — | — | US | disclosed |
| WO-2008012603-A1 | POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF DIFLUNISAL AND RELATED COMPOUNDS WITH VERY FAST SKIN PENETRATION RATE | TECHFIELDS BIOCHEM CO. LTD (CN) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183728-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | SLC5A1, GPR119, INSR | HSD17B10 740/4885KDM4E 4515/4885LMNA 206/4885 |
| US-20250099491-A1 | PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES WITH HIGH PENETRATION PRODRUGS OF ASPIRIN AND OTHER NSAIDS | PTGS1, PTGIS, PTGS2 | HSD17B10 560/4885KDM4E 3183/4885LMNA 1667/4885 |
| US-20140357680-A1 | COMPOSITIONS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | SLC5A1, INSR, GPR119 | HSD17B10 954/4885KDM4E 4409/4885LMNA 362/4885 |
| US-20170209404-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | HSD17B10 454/4885KDM4E 4795/4885LMNA 2799/4885 |
| US-20210353579-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | HSD17B10 454/4885KDM4E 4795/4885LMNA 2799/4885 |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | HSD17B10 454/4885KDM4E 4795/4885LMNA 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.